Literature DB >> 29844043

Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.

Zhaojing Zong1,2, Wei Jing1, Jin Shi3, Shu'an Wen1, Tingting Zhang1, Fengmin Huo1, Yuanyuan Shang1, Qian Liang1, Hairong Huang4, Yu Pang4.   

Abstract

Oxazolidinones are efficacious in treating mycobacterial infections, including tuberculosis (TB) caused by drug-resistant Mycobacterium tuberculosis In this study, we compared the in vitro activities and MIC distributions of delpazolid, a novel oxazolidinone, and linezolid against multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) in China. Additionally, genetic mutations in 23S rRNA, rplC, and rplD genes were analyzed to reveal potential mechanisms underlying the observed oxazolidinone resistance. A total of 240 M. tuberculosis isolates were included in this study, including 120 MDR-TB isolates and 120 XDR-TB isolates. Overall, linezolid and delpazolid MIC90 values for M. tuberculosis isolates were 0.25 mg/liter and 0.5 mg/liter, respectively. Based on visual inspection, we tentatively set epidemiological cutoff (ECOFF) values for MIC determinations for linezolid and delpazolid at 1.0 mg/liter and 2.0 mg/liter, respectively. Although no significant difference in resistance rates was observed between linezolid and delpazolid among XDR-TB isolates (P > 0.05), statistical analysis revealed a significantly greater proportion of linezolid-resistant isolates than delpazolid-resistant isolates within the MDR-TB group (P = 0.036). Seven (53.85%) of 13 linezolid-resistant isolates were found to harbor mutations within the three target genes. Additionally, 1 isolate exhibited an amino acid substitution (Arg126His) within the protein encoded by rplD that contributed to high-level resistance to linezolid (MIC of >16 mg/liter), compared to a delpazolid MIC of 0.25. In conclusion, in vitro susceptibility testing revealed that delpazolid antibacterial activity was comparable to that of linezolid. A novel mutation within rplD that endowed M. tuberculosis with linezolid, but not delpazolid, resistance was identified.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  MIC; delpazolid; linezolid; minimal inhibitory concentration; multidrug-resistant tuberculosis

Mesh:

Substances:

Year:  2018        PMID: 29844043      PMCID: PMC6105784          DOI: 10.1128/AAC.00165-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  José A Caminero; Giovanni Sotgiu; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Lancet Infect Dis       Date:  2010-09       Impact factor: 25.071

3.  TB Alliance regimen development for multidrug-resistant tuberculosis.

Authors:  S Murray; C Mendel; M Spigelman
Journal:  Int J Tuberc Lung Dis       Date:  2016-12-01       Impact factor: 2.373

4.  rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.

Authors:  Patrick Beckert; Doris Hillemann; Thomas A Kohl; Jörn Kalinowski; Elvira Richter; Stefan Niemann; Silke Feuerriegel
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

Review 5.  Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges.

Authors:  Gunar Günther
Journal:  Clin Med (Lond)       Date:  2014-06       Impact factor: 2.659

6.  In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China.

Authors:  Yu Pang; Huiwen Zheng; Yaoju Tan; Yuanyuan Song; Yanlin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 7.  Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Authors:  Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Jan-William C Alffenaar; Holly A Anger; Jose A Caminero; Paolo Castiglia; Saverio De Lorenzo; Giovanni Ferrara; Won-Jung Koh; Giesela F Schecter; Tae S Shim; Rupak Singla; Alena Skrahina; Antonio Spanevello; Zarir F Udwadia; Miquel Villar; Elisabetta Zampogna; Jean-Pierre Zellweger; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-04-10       Impact factor: 16.671

Review 8.  Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  H Cox; N Ford
Journal:  Int J Tuberc Lung Dis       Date:  2012-04       Impact factor: 2.373

9.  Polyphyletic emergence of linezolid-resistant staphylococci in the United States.

Authors:  Agnes Wong; Shilpa P Reddy; Davida S Smyth; Maria E Aguero-Rosenfeld; George Sakoulas; D Ashley Robinson
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

10.  Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus.

Authors:  Tae Sung Kim; Jin Ho Choe; Young Jae Kim; Chul-Su Yang; Hyun-Jin Kwon; Jinsun Jeong; Guehye Kim; Da Eun Park; Eun-Kyeong Jo; Young-Lag Cho; Jichan Jang
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

View more
  11 in total

Review 1.  Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors:  Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-05       Impact factor: 4.813

Review 2.  Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment.

Authors:  Filia Stephanie; Mutiara Saragih; Usman Sumo Friend Tambunan
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

3.  Molecular Analysis of Linezolid-Resistant Clinical Isolates of Mycobacterium abscessus.

Authors:  Meiping Ye; Liyun Xu; Yuzhen Zou; Bing Li; Qi Guo; Yongjie Zhang; Mengling Zhan; Benyong Xu; Fangyou Yu; Zhemin Zhang; Haiqing Chu
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

4.  Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa.

Authors:  Sean Wasserman; Gail Louw; Limpho Ramangoaela; Garrick Barber; Cindy Hayes; Shaheed Vally Omar; Gary Maartens; Clifton Barry; Taeksun Song; Graeme Meintjes
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

5.  In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant Mycobacterium tuberculosis Isolated from Retreatment Tuberculosis Patients.

Authors:  Ruoyan Ying; Xiaochen Huang; Yaxian Gao; Jie Wang; Yidian Liu; Wei Sha; Hua Yang
Journal:  Infect Drug Resist       Date:  2021-09-14       Impact factor: 4.003

6.  In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China.

Authors:  Xia Yu; Fengmin Huo; Fen Wang; Shu'an Wen; Guanglu Jiang; Yi Xue; Lingling Dong; Liping Zhao; Rui Zhu; Hairong Huang
Journal:  Infect Drug Resist       Date:  2021-11-09       Impact factor: 4.003

7.  K2S2O8-mediated radical cyclisation of 2-alkynylthioanisoles or -selenoanisoles: a green and regioselective route to 3-nitrobenzothiophenes and benzoselenophenes.

Authors:  Shi-Chao Lu; Botao Wu; Shi-Peng Zhang; Ya-Ling Gong; Shu Xu
Journal:  RSC Adv       Date:  2020-05-19       Impact factor: 3.361

Review 8.  Mycobacterium tuberculosis and Pulmonary Rehabilitation: From Novel Pharmacotherapeutic Approaches to Management of Post-Tuberculosis Sequelae.

Authors:  Andreea-Daniela Meca; Liliana Mititelu-Tarțău; Maria Bogdan; Lorena Anda Dijmarescu; Ana-Maria Pelin; Liliana Georgeta Foia
Journal:  J Pers Med       Date:  2022-04-02

9.  Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis.

Authors:  Marjorie Z Imperial; Jerry R Nedelman; Francesca Conradie; R M Savic
Journal:  Clin Infect Dis       Date:  2022-05-30       Impact factor: 20.999

Review 10.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.